Janux therapeutics highlights pipeline progress and best-in-class potential of novel bispecific platform for autoimmune diseases at virtual r&d day

San diego--(business wire)---- $janx--janux therapeutics, inc. (nasdaq: janx) (janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its tumor activated t cell engager (tractr), tumor activated immunomodulator (tracir), and adaptive immune response modulator (arm) platforms, will host its virtual r&d day today at 1:30 pm pt. the event will highlight the company's continued momentum in advancing its novel imm.
JANX Ratings Summary
JANX Quant Ranking